metformin has been researched along with Depression in 46 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 9.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| "Data on comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in subjects with polycystic ovary syndrome (PCOS) are scarce." | 9.27 | Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Asemi, Z; Bahmani, F; Foroozanfard, F; Jamilian, H; Jamilian, M, 2018) |
| "Emerging evidence showed metformin may have pleiotropic effects on ameliorating depression." | 8.12 | Association of metformin and depression in patients with type 2 diabetes. ( Hu, Y; Qin, X; Wang, S; Wu, J; Wu, T; Wu, Y; Yang, R; Yu, H, 2022) |
| "Metformin attenuated the depression-like behaviors induced by CORT." | 8.02 | Metformin Attenuates the Metabolic Disturbance and Depression-like Behaviors Induced by Corticosterone and Mediates the Glucose Metabolism Pathway. ( Guan, Y; Guo, Y; Hao, Y; Huang, X; Lang, X; Li, Z; Tong, Y; Xie, X, 2021) |
| "Our findings suggest that metformin can produce antidepressant effects, which provides empirical insights into the clinical value of metformin in the prevention and therapy of depression." | 7.96 | Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. ( Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J, 2020) |
| "According to the data obtained, methamphetamine caused significant depression, anxiety, motor activity disturbances and cognition impairment in experimental animals." | 7.91 | Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways. ( Karami, L; Kermanshahi, S; Keshavarzi, S; Motaghinejad, M; Motevalian, M; Sadr, S, 2019) |
| "We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS)." | 7.91 | A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. ( Aghamohammadzadeh, N; Erensoy, H; Ghafarzadeh, S; Nader, ND; Niafar, M, 2019) |
| "Overweight status, poor physical capabilities and low activity level, and the presence of more than two additional illnesses were risk factors for depression in elderly diabetic patients, and metformin was a protective factor against depression in elderly diabetic patients." | 7.91 | Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. ( Chen, F; Huang, T; Liu, T; Ma, G; Wang, D; Wang, Y; Wei, G; Wei, Q, 2019) |
| "05), and in combination with sitagliptin (p < 0." | 5.91 | Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study. ( Athar, M; Garg, A; Khan, MA; Kohli, S; Parveen, R; Vohora, D, 2023) |
| "However, the mechanisms and treatments for depression in AR remain underexplored." | 5.91 | Metformin Improves Comorbid Depressive Symptoms in Mice with Allergic Rhinitis by Reducing Olfactory Bulb Damage. ( Chen, S; Cong, J; Gao, Z; Guan, M; Liu, P; Lv, H; Wang, Y; Xie, Y; Xu, Y, 2023) |
| "In addition, the benefits of metformin treatment of depression have been documented in a range of rodent studies and human trials, but few studies have probed into the effect of metformin on and the related mechanism in depressed elderly mice, especially in those APOE4 carriers." | 5.72 | Metformin alleviates the depression-like behaviors of elderly apoE4 mice via improving glucose metabolism and mitochondrial biogenesis. ( Chen, X; Dai, X; Lin, Y; Zhang, J, 2022) |
| "Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions." | 5.62 | Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α. ( Abed, AF; Alfaraj, M; Hall, FS; Hammad, AM; Ibrahim, YA; Jarrar, Y; Khdair, SI, 2021) |
| "Metformin (25 mg/kg) was administered daily by oral gavage for 2 weeks." | 5.62 | Protective effect of metformin against ovariectomy induced depressive- and anxiety-like behaviours in rats: role of oxidative stress. ( Erdem, S; Ergenc, M; Ozacmak, VH; Sayan Özaçmak, H; Turan, I, 2021) |
| "Comorbid depression was induced by five inescapable foot-shocks (2mA, 2ms duration) at 10s intervals on days 1, 5, 7, and 10." | 5.46 | Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats. ( Kumar, M; Nayak, PK; Shivavedi, N; Tej, GNVC, 2017) |
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 5.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| "Data on comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in subjects with polycystic ovary syndrome (PCOS) are scarce." | 5.27 | Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Asemi, Z; Bahmani, F; Foroozanfard, F; Jamilian, H; Jamilian, M, 2018) |
| "Secondary analysis of men (n=886) participating in the Diabetes Prevention Program which randomized glucose-intolerant, overweight men to ILS, metformin, or placebo between 1996 and 1999." | 5.22 | Testosterone and depressive symptoms among men in the Diabetes Prevention Program. ( Aroda, VR; Barrett-Connor, E; Bray, GA; Christophi, CA; Golden, SH; Horton, ES; Kim, C; Labrie, F; Mather, KJ; Pi-Sunyer, X, 2016) |
| "Diabetes Prevention Program participants in three treatment arms (intensive life style, metformin, placebo) were assessed for diabetes, glucose control, ADM use, and DS, measured using the Beck Depression Inventory (BDI)." | 5.20 | Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study. ( Barrett-Connor, E; Carnethon, MR; de Groot, M; Horton, ES; Knowler, WC; Ma, Y; Marrero, DG; Price, DW, 2015) |
| "DPP participants (n = 3,187) in three treatment arms (intensive lifestyle [ILS], metformin [MET], and placebo [PLB]) completed the Beck Depression Inventory (BDI) and reported their use of antidepressant medication at randomization and throughout the study (average duration in study 3." | 5.13 | Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program. ( Barrett-Connor, EL; Haffner, SM; Kahn, SE; Knowler, WC; Ma, Y; Marrero, DG; Peyrot, M; Price, DW; Rubin, RR, 2008) |
| "The use of metformin was associated with lower odds for symptoms of depression (OR 0." | 4.31 | Associations between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus - A Register-based Study. ( Kullenberg, H; Kumlin, M; Nyström, T; Svedberg, MM; Wibom, M, 2023) |
| "Linear regression models examined cross-sectional associations of baseline depression symptoms and diabetes distress with adherence to metformin, self-management, and HbA1c, adjusting for covariates." | 4.31 | Emotional distress, self-management, and glycemic control among participants enrolled in the glycemia reduction approaches in diabetes: A comparative effectiveness (GRADE) study. ( Bebu, I; Brown-Friday, J; Cherrington, A; Crespo-Ramos, G; Ehrmann, D; Gonzalez, JS; Hoogendoorn, CJ; Krause-Steinrauf, H; Naik, AD; Walker, E; Waltje, A, 2023) |
| "Emerging evidence showed metformin may have pleiotropic effects on ameliorating depression." | 4.12 | Association of metformin and depression in patients with type 2 diabetes. ( Hu, Y; Qin, X; Wang, S; Wu, J; Wu, T; Wu, Y; Yang, R; Yu, H, 2022) |
| "Real-life population-based data suggest a positive effect of metformin on depression rates." | 3.96 | Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. ( Berk, M; Ekstrøm, CT; Gerds, TA; Kessing, LV; Knop, FK; Rytgaard, HC, 2020) |
| "Our findings suggest that metformin can produce antidepressant effects, which provides empirical insights into the clinical value of metformin in the prevention and therapy of depression." | 3.96 | Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. ( Chen, X; Dai, X; Fang, W; Hong, L; Huang, W; Ye, Q; Zhang, J, 2020) |
| "Overweight status, poor physical capabilities and low activity level, and the presence of more than two additional illnesses were risk factors for depression in elderly diabetic patients, and metformin was a protective factor against depression in elderly diabetic patients." | 3.91 | Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. ( Chen, F; Huang, T; Liu, T; Ma, G; Wang, D; Wang, Y; Wei, G; Wei, Q, 2019) |
| "We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS)." | 3.91 | A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. ( Aghamohammadzadeh, N; Erensoy, H; Ghafarzadeh, S; Nader, ND; Niafar, M, 2019) |
| "Metformin has a therapeutic benefit against CUMS-induced depression, which provides a new treatment for patients with diabetes mellitus complicated with depression." | 3.91 | [Effects of metformin on depressive behavior in chronic stress rats]. ( Cheng, X; Fan, M; Li, GF; Zhao, M; Zhao, T; Zhu, LL, 2019) |
| "According to the data obtained, methamphetamine caused significant depression, anxiety, motor activity disturbances and cognition impairment in experimental animals." | 3.91 | Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways. ( Karami, L; Kermanshahi, S; Keshavarzi, S; Motaghinejad, M; Motevalian, M; Sadr, S, 2019) |
| "To evaluate the impact of depression on NASH through the involvement of JNK1 and to assess the effect of sitagliptin and metformin on hepatic JNK1 expression in both NASH and NASH associated with depression." | 3.85 | Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress. ( Abd-Elaziz, LF; Aboul-Fotouh, S; El-Kharashi, OA; Magdy, YM; Nabih, ES; Shaker, SM, 2017) |
| "To identify distinct temporal likelihoods of age-related comorbidity (ARC) diagnoses: cardiovascular diseases (CVD), cancer, depression, dementia, and frailty-related diseases (FRD) in older men with type 2 diabetes (T2D) but ARC naïve initially, and assess the heterogeneous effects of metformin on ARCs and mortality." | 3.85 | Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. ( Espinoza, SE; Habib, SL; Jo, B; Lorenzo, C; Wang, CP, 2017) |
| "Depression is the most known complication of type 2 diabetes mellitus (T2DM)." | 3.11 | Effect of aerobic exercise as a treatment on type 2 diabetes mellitus with depression-like behavior zebrafish. ( Fang, Y; Gu, X; He, Z; Hu, X; Jin, L; Liu, F; Ma, J; Sun, D; Wang, L; Wu, W; Yang, Q; Zhang, X, 2022) |
| "It is thought that it exerts its anti-cancer effect through the inhibition of the mammalian target of rapamycin (mTOR) signalling pathway." | 2.61 | The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth. ( Amin, S; Lux, A; O'Callaghan, F, 2019) |
| "Depression is a common comorbidity in diabetes but conventional antidepressant treatments do not consistently improve outcomes." | 2.58 | Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials. ( Hopkins, CWP; Ismail, K; Moulton, CD; Stahl, D, 2018) |
| "Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015) |
| "However, the mechanisms and treatments for depression in AR remain underexplored." | 1.91 | Metformin Improves Comorbid Depressive Symptoms in Mice with Allergic Rhinitis by Reducing Olfactory Bulb Damage. ( Chen, S; Cong, J; Gao, Z; Guan, M; Liu, P; Lv, H; Wang, Y; Xie, Y; Xu, Y, 2023) |
| "05), and in combination with sitagliptin (p < 0." | 1.91 | Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study. ( Athar, M; Garg, A; Khan, MA; Kohli, S; Parveen, R; Vohora, D, 2023) |
| "In addition, the benefits of metformin treatment of depression have been documented in a range of rodent studies and human trials, but few studies have probed into the effect of metformin on and the related mechanism in depressed elderly mice, especially in those APOE4 carriers." | 1.72 | Metformin alleviates the depression-like behaviors of elderly apoE4 mice via improving glucose metabolism and mitochondrial biogenesis. ( Chen, X; Dai, X; Lin, Y; Zhang, J, 2022) |
| "Among the patients who treat depression, about 50% do not show significant improvement due to the limited efficacy of the treatment." | 1.72 | Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. ( Costa, BLDSAD; Duarte-Silva, EP; Melo, MG; Mendonça, IP; Oliveira, WH; Paiva, IHR; Peixoto, CA; Silva, RSD, 2022) |
| "Depression was diagnosed in 2." | 1.72 | Depression and the risk of hospitalization in type 2 diabetes patients: A nested case-control study accounting for non-persistence to antidiabetic treatment. ( Demers, É; Guénette, L; Lunghi, C; Tardif, I; Zongo, A, 2022) |
| "Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions." | 1.62 | Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α. ( Abed, AF; Alfaraj, M; Hall, FS; Hammad, AM; Ibrahim, YA; Jarrar, Y; Khdair, SI, 2021) |
| "Metformin (25 mg/kg) was administered daily by oral gavage for 2 weeks." | 1.62 | Protective effect of metformin against ovariectomy induced depressive- and anxiety-like behaviours in rats: role of oxidative stress. ( Erdem, S; Ergenc, M; Ozacmak, VH; Sayan Özaçmak, H; Turan, I, 2021) |
| "Comorbid depression was induced by five inescapable foot-shocks (2mA, 2ms duration) at 10s intervals on days 1, 5, 7, and 10." | 1.46 | Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats. ( Kumar, M; Nayak, PK; Shivavedi, N; Tej, GNVC, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (6.52) | 29.6817 |
| 2010's | 20 (43.48) | 24.3611 |
| 2020's | 23 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mendonça, IP | 1 |
| Paiva, IHR | 1 |
| Duarte-Silva, EP | 1 |
| Melo, MG | 1 |
| Silva, RSD | 1 |
| Oliveira, WH | 1 |
| Costa, BLDSAD | 1 |
| Peixoto, CA | 1 |
| Lin, Y | 1 |
| Dai, X | 2 |
| Zhang, J | 2 |
| Chen, X | 3 |
| Tardif, I | 1 |
| Guénette, L | 1 |
| Zongo, A | 1 |
| Demers, É | 1 |
| Lunghi, C | 1 |
| Wium-Andersen, IK | 1 |
| Osler, M | 1 |
| Jørgensen, MB | 1 |
| Rungby, J | 1 |
| Wium-Andersen, MK | 1 |
| Yang, J | 1 |
| Zhang, Z | 1 |
| Xie, Z | 1 |
| Bai, L | 1 |
| Xiong, P | 1 |
| Chen, F | 2 |
| Zhu, T | 1 |
| Peng, Q | 1 |
| Wu, H | 1 |
| Zhou, Y | 1 |
| Ma, Y | 3 |
| Zhang, Y | 1 |
| Chen, M | 1 |
| Gao, J | 1 |
| Tian, W | 1 |
| Shi, K | 1 |
| Du, Y | 1 |
| Duan, Y | 1 |
| Wang, H | 1 |
| Xu, Y | 4 |
| Kuang, YQ | 1 |
| Zhu, M | 1 |
| Yu, J | 1 |
| Wang, K | 1 |
| Wang, L | 1 |
| Ma, J | 1 |
| Wu, W | 1 |
| Fang, Y | 1 |
| Liu, F | 1 |
| Yang, Q | 1 |
| Hu, X | 1 |
| Gu, X | 1 |
| He, Z | 1 |
| Sun, D | 1 |
| Jin, L | 1 |
| Zhang, X | 1 |
| Yu, H | 1 |
| Yang, R | 1 |
| Wu, J | 1 |
| Wang, S | 1 |
| Qin, X | 1 |
| Wu, T | 1 |
| Hu, Y | 1 |
| Wu, Y | 1 |
| Athar, M | 2 |
| Garg, A | 2 |
| Khan, MA | 2 |
| Parveen, R | 2 |
| Kohli, S | 2 |
| Vohora, D | 2 |
| Gonzalez, JS | 1 |
| Krause-Steinrauf, H | 1 |
| Bebu, I | 1 |
| Crespo-Ramos, G | 1 |
| Hoogendoorn, CJ | 1 |
| Naik, AD | 1 |
| Waltje, A | 1 |
| Walker, E | 1 |
| Ehrmann, D | 1 |
| Brown-Friday, J | 1 |
| Cherrington, A | 1 |
| Kullenberg, H | 1 |
| Wibom, M | 1 |
| Kumlin, M | 1 |
| Nyström, T | 1 |
| Svedberg, MM | 1 |
| Lv, H | 2 |
| Gao, Z | 2 |
| Wang, Y | 3 |
| Chen, S | 1 |
| Liu, P | 1 |
| Xie, Y | 2 |
| Guan, M | 2 |
| Cong, J | 1 |
| Wei, G | 1 |
| Liu, T | 1 |
| Huang, T | 1 |
| Wei, Q | 1 |
| Ma, G | 1 |
| Wang, D | 1 |
| Fang, W | 1 |
| Hong, L | 1 |
| Huang, W | 1 |
| Ye, Q | 1 |
| Yang, S | 1 |
| Hao, Y | 2 |
| Meng, X | 1 |
| Guo, QJ | 1 |
| Shan, J | 1 |
| Xu, YF | 1 |
| Hu, YY | 1 |
| Huo, CL | 1 |
| Song, JY | 1 |
| Wang, CQ | 1 |
| Zhou, H | 1 |
| Yu, CQ | 1 |
| Huang, Q | 1 |
| Nesci, V | 1 |
| Russo, E | 1 |
| Arcidiacono, B | 1 |
| Citraro, R | 1 |
| Tallarico, M | 1 |
| Constanti, A | 1 |
| Brunetti, A | 1 |
| De Sarro, G | 1 |
| Leo, A | 1 |
| El Massry, M | 1 |
| Alaeddine, LM | 1 |
| Ali, L | 1 |
| Saad, C | 1 |
| Eid, AA | 1 |
| Woo, YS | 1 |
| Lim, HK | 1 |
| Wang, SM | 1 |
| Bahk, WM | 1 |
| Kessing, LV | 1 |
| Rytgaard, HC | 1 |
| Ekstrøm, CT | 1 |
| Knop, FK | 1 |
| Berk, M | 1 |
| Gerds, TA | 1 |
| Tong, Y | 1 |
| Guo, Y | 1 |
| Lang, X | 1 |
| Huang, X | 1 |
| Xie, X | 1 |
| Guan, Y | 1 |
| Li, Z | 1 |
| Turan, I | 1 |
| Sayan Özaçmak, H | 1 |
| Erdem, S | 1 |
| Ergenc, M | 1 |
| Ozacmak, VH | 1 |
| Hammad, AM | 1 |
| Ibrahim, YA | 1 |
| Khdair, SI | 1 |
| Hall, FS | 1 |
| Alfaraj, M | 1 |
| Jarrar, Y | 1 |
| Abed, AF | 1 |
| Moulton, CD | 2 |
| Rokakis, AS | 1 |
| Pickup, JC | 1 |
| Young, AH | 1 |
| Stahl, D | 2 |
| Ismail, K | 2 |
| Shivavedi, N | 1 |
| Kumar, M | 1 |
| Tej, GNVC | 1 |
| Nayak, PK | 1 |
| Jamilian, H | 1 |
| Jamilian, M | 1 |
| Foroozanfard, F | 1 |
| Afshar Ebrahimi, F | 1 |
| Bahmani, F | 1 |
| Asemi, Z | 1 |
| Hopkins, CWP | 1 |
| Erensoy, H | 1 |
| Niafar, M | 1 |
| Ghafarzadeh, S | 1 |
| Aghamohammadzadeh, N | 1 |
| Nader, ND | 1 |
| Amin, S | 1 |
| Lux, A | 1 |
| O'Callaghan, F | 1 |
| Liu, W | 2 |
| Liu, J | 1 |
| Huang, Z | 1 |
| Cui, Z | 1 |
| Li, L | 1 |
| Qi, Z | 1 |
| Keshavarzi, S | 1 |
| Kermanshahi, S | 1 |
| Karami, L | 1 |
| Motaghinejad, M | 1 |
| Motevalian, M | 1 |
| Sadr, S | 1 |
| Zemdegs, J | 1 |
| Martin, H | 1 |
| Pintana, H | 1 |
| Bullich, S | 1 |
| Manta, S | 1 |
| Marqués, MA | 1 |
| Moro, C | 1 |
| Layé, S | 1 |
| Ducrocq, F | 1 |
| Chattipakorn, N | 1 |
| Chattipakorn, SC | 1 |
| Rampon, C | 1 |
| Pénicaud, L | 1 |
| Fioramonti, X | 1 |
| Guiard, BP | 1 |
| Li, GF | 1 |
| Zhao, M | 1 |
| Zhao, T | 1 |
| Cheng, X | 1 |
| Fan, M | 1 |
| Zhu, LL | 1 |
| Guo, M | 1 |
| Mi, J | 1 |
| Jiang, QM | 1 |
| Xu, JM | 1 |
| Tang, YY | 1 |
| Tian, G | 1 |
| Wang, B | 1 |
| Marrero, DG | 2 |
| de Groot, M | 1 |
| Horton, ES | 2 |
| Price, DW | 2 |
| Barrett-Connor, E | 2 |
| Carnethon, MR | 1 |
| Knowler, WC | 2 |
| Gődény, S | 1 |
| Csenteri, OK | 1 |
| Katz, LL | 1 |
| Anderson, BJ | 1 |
| McKay, SV | 1 |
| Izquierdo, R | 1 |
| Casey, TL | 1 |
| Higgins, LA | 1 |
| Wauters, A | 1 |
| Hirst, K | 1 |
| Nadeau, KJ | 1 |
| Kim, C | 1 |
| Aroda, VR | 1 |
| Mather, KJ | 1 |
| Christophi, CA | 1 |
| Pi-Sunyer, X | 1 |
| Bray, GA | 1 |
| Labrie, F | 1 |
| Golden, SH | 1 |
| Krysiak, R | 1 |
| Drosdzol-Cop, A | 1 |
| Skrzypulec-Plinta, V | 1 |
| Okopień, B | 1 |
| Magdy, YM | 1 |
| El-Kharashi, OA | 1 |
| Nabih, ES | 1 |
| Shaker, SM | 1 |
| Abd-Elaziz, LF | 1 |
| Aboul-Fotouh, S | 1 |
| Aswar, U | 1 |
| Chepurwar, S | 1 |
| Shintre, S | 1 |
| Aswar, M | 1 |
| Wang, CP | 1 |
| Lorenzo, C | 1 |
| Habib, SL | 1 |
| Jo, B | 1 |
| Espinoza, SE | 1 |
| Wagner, J | 1 |
| Allen, NA | 1 |
| Swalley, LM | 1 |
| Melkus, GD | 1 |
| Whittemore, R | 1 |
| Moll, E | 1 |
| van Wely, M | 1 |
| Lambalk, CB | 1 |
| Bossuyt, PM | 1 |
| van der Veen, F | 1 |
| Rubin, RR | 1 |
| Peyrot, M | 1 |
| Barrett-Connor, EL | 1 |
| Kahn, SE | 1 |
| Haffner, SM | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
6 reviews available for metformin and Depression
| Article | Year |
|---|---|
Metformin: A Growing Journey from Glycemic Control to the Treatment of Alzheimer's Disease and Depression.
Topics: Alzheimer Disease; Depression; Diabetes Mellitus, Type 2; Glycemic Control; Humans; Hypoglycemic Age | 2021 |
Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression-A Literature Review.
Topics: Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Huma | 2020 |
Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
Topics: Adult; Antidepressive Agents; Blood Glucose; Clinical Trials as Topic; Depression; Diabetes Mellitus | 2018 |
The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumour growth.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Cell Line, Tumor; Clinical Trials as Topic; Cogniti | 2019 |
[Evidence-based therapy of polycystic ovarian syndrome].
Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace | 2015 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
11 trials available for metformin and Depression
| Article | Year |
|---|---|
Effect of aerobic exercise as a treatment on type 2 diabetes mellitus with depression-like behavior zebrafish.
Topics: Animals; Blood Glucose; Depression; Diabetes Mellitus, Type 2; Metformin; Zebrafish | 2022 |
Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study.
Topics: Adult; Anxiety; Comorbidity; Depression; Female; Humans; Inflammasomes; Metformin; NLR Family, Pyrin | 2020 |
SITAgliptin for Depressive Symptoms in Type 2 Diabetes: A Feasibility Randomized Controlled Trial.
Topics: Depression; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Feasibility S | 2021 |
Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anxiety; Biomarkers; Depression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; In | 2018 |
Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus.
Topics: Adult; Antidepressive Agents; Cognition; Depression; Diabetes Mellitus, Type 2; Double-Blind Method; | 2014 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Depressive symptoms, antidepressant medication use, and new onset of diabetes in participants of the diabetes prevention program and the diabetes prevention program outcomes study.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Ag | 2015 |
Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Body Mass Index; Child; Cohort Studies; Depression; Diabetes Mellitus, Ty | 2016 |
Testosterone and depressive symptoms among men in the Diabetes Prevention Program.
Topics: Adult; Depression; Diabetes Mellitus; Follow-Up Studies; Glucose Metabolism Disorders; Humans; Hypog | 2016 |
Sexual Functioning and Depressive Symptoms in Women with Diabetes and Prediabetes Receiving Metformin Therapy: A Pilot Study.
Topics: Adult; Coitus; Depression; Diabetes Mellitus, Type 2; Female; Humans; Metformin; Prediabetic State | 2017 |
Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo.
Topics: Adult; Anxiety; Clomiphene; Depression; Double-Blind Method; Female; Fertility Agents, Female; Human | 2012 |
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program.
Topics: Adult; Antidepressive Agents; Depression; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Li | 2008 |
29 other studies available for metformin and Depression
| Article | Year |
|---|---|
Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinsońs disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity.
Topics: Animals; Antidepressive Agents, Second-Generation; Blotting, Western; Depression; Drug Therapy, Comb | 2022 |
Metformin alleviates the depression-like behaviors of elderly apoE4 mice via improving glucose metabolism and mitochondrial biogenesis.
Topics: Aging; Animals; Apolipoprotein E3; Apolipoprotein E4; Behavior, Animal; Depression; Disease Models, | 2022 |
Depression and the risk of hospitalization in type 2 diabetes patients: A nested case-control study accounting for non-persistence to antidiabetic treatment.
Topics: Cardiovascular Diseases; Case-Control Studies; Depression; Diabetes Mellitus, Type 2; Hospitalizatio | 2022 |
Diabetes, antidiabetic medications and risk of depression - A population-based cohort and nested case-control study.
Topics: Case-Control Studies; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glu | 2022 |
Metformin modulates microbiota-derived inosine and ameliorates methamphetamine-induced anxiety and depression-like withdrawal symptoms in mice.
Topics: Amphetamine-Related Disorders; Animals; Anxiety; Depression; Inosine; Metformin; Methamphetamine; Mi | 2022 |
Association of metformin and depression in patients with type 2 diabetes.
Topics: Cohort Studies; Depression; Diabetes Mellitus, Type 2; Female; Glycoside Hydrolase Inhibitors; Human | 2022 |
Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study.
Topics: Blood Glucose; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Thera | 2023 |
Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study.
Topics: Blood Glucose; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Thera | 2023 |
Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study.
Topics: Blood Glucose; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Thera | 2023 |
Metformin alone and in combination with sitagliptin induces depression and impairs quality of life in type 2 diabetes mellitus patients: An observational study.
Topics: Blood Glucose; Depression; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Thera | 2023 |
Emotional distress, self-management, and glycemic control among participants enrolled in the glycemia reduction approaches in diabetes: A comparative effectiveness (GRADE) study.
Topics: Aged; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; G | 2023 |
Associations between the Use of Metformin and Behavioral and Psychological Symptoms in Patients with Alzheimer´s Disease, and Type 2 Diabetes Mellitus - A Register-based Study.
Topics: Aged, 80 and over; Alzheimer Disease; Cross-Sectional Studies; Depression; Diabetes Mellitus, Type 2 | 2023 |
Metformin Improves Comorbid Depressive Symptoms in Mice with Allergic Rhinitis by Reducing Olfactory Bulb Damage.
Topics: AMP-Activated Protein Kinases; Animals; Depression; Disease Models, Animal; Metformin; Mice; Olfacto | 2023 |
TET2 deficiency promotes anxiety and depression-like behaviors by activating NLRP3/IL-1β pathway in microglia of allergic rhinitis mice.
Topics: Animals; Anxiety; Depression; Dioxygenases; DNA-Binding Proteins; Inflammasomes; Metformin; Mice; Mi | 2023 |
Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition.
Topics: Aged; Case-Control Studies; Depression; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Male | 2019 |
Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation.
Topics: Acetylation; AMP-Activated Protein Kinases; Animals; Antidepressive Agents; Brain-Derived Neurotroph | 2020 |
Effects of metformin on lipopolysaccharide-induced depressive-like behavior in mice and its mechanisms.
Topics: Animals; Behavior, Animal; Depression; Inflammation; Lipopolysaccharides; Male; Metformin; Mice; Mic | 2020 |
Metabolic Alterations Predispose to Seizure Development in High-Fat Diet-Treated Mice: the Role of Metformin.
Topics: Animals; Anxiety; Avoidance Learning; Behavior, Animal; Blood Glucose; Body Composition; Depression; | 2020 |
Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Denmark; Depression; Diabetes Mellitus, Type | 2020 |
Metformin Attenuates the Metabolic Disturbance and Depression-like Behaviors Induced by Corticosterone and Mediates the Glucose Metabolism Pathway.
Topics: Animals; Chromatography, Liquid; Corticosterone; Depression; Glucose; Humans; Metformin; Rats; Tande | 2021 |
Protective effect of metformin against ovariectomy induced depressive- and anxiety-like behaviours in rats: role of oxidative stress.
Topics: Animals; Anxiety; Blood Glucose; Depression; Female; Glutathione; Hippocampus; Malondialdehyde; Metf | 2021 |
Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α.
Topics: Anabolic Agents; Animals; Anti-Inflammatory Agents; Behavior, Animal; Cytokines; Depression; Disease | 2021 |
Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats.
Topics: Animals; Ascorbic Acid; Biogenic Monoamines; Blood Glucose; Comorbidity; Corticosterone; Cytokines; | 2017 |
A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Anxiety; Blood Glucose; Body Mass Index; Depression; Female; Humans; Hypoglycemic | 2019 |
Possible role of GLP-1 in antidepressant effects of metformin and exercise in CUMS mice.
Topics: Animals; Antidepressive Agents; bcl-2-Associated X Protein; Corticosterone; Depression; Depressive D | 2019 |
Protective role of metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: The role of CREB/BDNF and Akt/GSK3 signaling pathways.
Topics: Animals; Anxiety; Brain-Derived Neurotrophic Factor; Central Nervous System Stimulants; Cognitive Dy | 2019 |
Metformin Promotes Anxiolytic and Antidepressant-Like Responses in Insulin-Resistant Mice by Decreasing Circulating Branched-Chain Amino Acids.
Topics: Amino Acids, Branched-Chain; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Depressio | 2019 |
[Effects of metformin on depressive behavior in chronic stress rats].
Topics: Animals; Depression; Hippocampus; Male; Metformin; Random Allocation; Rats; Rats, Sprague-Dawley; St | 2019 |
Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.
Topics: Animals; Behavior, Animal; Biomarkers; Chronic Disease; Depression; Diet, High-Fat; Disease Models, | 2017 |
Telmisartan attenuates diabetes induced depression in rats.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Depress | 2017 |
Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aging; Cardiovascular Diseases; Cohort Studies; Comorbidity; Dementia; Depr | 2017 |
Depression, depression treatment, and insulin sensitivity in adults at risk for type 2 diabetes.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Connecticut; Depression; Diabetes Mellitus, Type | 2009 |